

Lower limb
Heel spur, plantar heel pain and tibialis posterior dysfunction
Anthony Baillon
Updated · published
A hard lump under the arch of the foot, which does not always hurt, which grows slowly, and which almost everyone first takes for plantar fasciitis.

A painful mass on weight-bearing, under the arch of the foot, suggests a benign fibromatosis with no causal treatment: the first measure is mechanical offloading of the nodule.
15.2%of men with Dupuytren's disease who also have plantar nodules
What follows covers each of these points in detail, with sources. It is there if you need it.
This topic is taught in a course: Heel spur, plantar heel pain and tibialis posterior dysfunction, online with Anthony Baillon.
1 / 11
10 article chapters · 35 min in total
Understanding◔ 3 min
It is the same process as Dupuytren's disease, but in a foot that bears the weight of the body.
Background◔ 5 min
In men with Dupuytren's disease, plantar nodules are found in 15.2 % of cases, versus 3.9 % in controls.
Multiple sites◔ 4 min
Three sites, one single process: palmar, plantar and penile forms share the same biology.
Recognising◔ 3 min
The nodule is bound to the fascia: it does not roll like a lipoma and hardens with the windlass manoeuvre.
Imaging◔ 2 min
A genuine plantar fibroma can look like a sarcoma on MRI, a real diagnostic trap.
Role of the physiotherapist◔ 5 min
Of 233 patients in 25 studies, only 35 received conservative treatment, against 178 operated on.
Radiotherapy◔ 3 min
The LedRad trial shows relief in 74 % of irradiated patients versus 56 % under placebo.
Operating◔ 2 min
Recurrence depends on the width of the resection, and on nothing else: 67 % with local resection, 27 % after fasciectomy.
Case reports◔ 3 min
A 48-year-old man obtained complete disappearance of pain after three sessions of shockwaves.
In practice◔ 5 min
The toe contracture the patient fears is the exception, not the rule, unlike in the hand.
Train on this


Lower limb
Anthony Baillon
Next comes practice: the course that teaches this topic, with Anthony Baillon.
Our courses on this topic may be covered by DPC or FIFPL, the French continuing-education funding schemes, depending on your profession and situation.
A hard lump under the arch of the foot, which does not always hurt, which grows slowly, and which almost everyone first takes for plantar fasciitis. Yet it is a different disease, a first cousin of Dupuytren's disease, for which a single treatment has been validated against placebo, and that treatment is neither surgery nor physiotherapy.
A synthesis written from primary sources checked one by one on PubMed: identifier resolved, journal and year verified, abstract read before citation. Complete bibliography at the end of the article.
Ledderhose disease in three figures
A strong family link with the hand, a treatment that has passed the placebo test, a surgery that recurs
Sources: Gudmundsson KG, Jónsson T, Arngrímsson R. Foot Ankle Int 2013;34(6):841-845 (PMID 23386754); de Haan A et al. Radiother Oncol 2023;185:109718 (PMID 37211283); Anwander H et al. Foot Ankle Spec 2024;17(2):109-116 (PMID 34369197).
What to take away before reading the rest
Understanding what this disease is doing spares you a long detour: it is the same tissue as in the palm, at the same cellular stage, but in a foot that bears the weight of the body, and that last point changes almost everything else.
Ledderhose disease belongs to the group of superficial fibromatoses, alongside Dupuytren's disease (palmar fibromatosis) and Peyronie's disease (penile involvement). All of them rest on the same process: a benign proliferation of fibroblasts and myofibroblasts, producing excess collagen.
A pathology review devoted to both sites describes a common histology, a bland spindle-cell proliferation of bluish appearance, with a variable amount of background collagen depending on the age of the lesion1. The authors above all stress the decisive clinical difference: palmar fibromatosis leads to nodules and then to digital contracture, whereas plantar fibromatosis produces often painful nodules but does not usually lead to contracture1.
This is the nuance to explain to the patient who has a relative who has had hand surgery and who fears being “no longer able to straighten the toes”. Toe contracture exists, but it is rare2 ; what causes the trouble is the lump under the foot.
The topography is stereotyped and it is a diagnostic argument. The nodules sit on the central or medial cord of the plantar aponeurosis, in proportions that vary between series: an old, small ultrasound series (14 patients, 25 nodules) found them medial in 60 % of cases and central in 40 %21, whereas the largest MRI series, retrospective and from a tertiary centre (196 cases), finds the central cord involved in 83 % of cases and the medial cord in 15 %, with several cords involved in 14 % of cases22. Along the length of the fascia, an ultrasound series of 57 fibromas in 43 patients measured their distribution: 84 % were located in the middle third of the plantar fascia3.
This detail explains two things. First, why the pain is not at the heel: it lies under the arch, in front of the heel, exactly where plantar fasciitis does not hurt. Second, why footwear and weight-bearing govern the complaint: a nodule in the middle of the arch is crushed at every step between the ground and the bone.
No aetiology is established, and the reviews say so bluntly: there is no causal treatment, management remains symptomatic2. The associations reported in the literature are, for their part, fairly consistent from one review to another: trauma, diabetes, anticonvulsant use, adhesive capsulitis of the shoulder, alcohol consumption and liver disease4.
They must be handled with the caution appropriate to associations drawn from case series: they guide the history, they do not explain the disease, and they are not treated. The only link whose magnitude has been measured in a cohort with a control group is the one with Dupuytren's disease, and that is the subject of the next chapter.
Ledderhose disease is not a plantar fasciitis that has gone wrong: it is a disease of the hand that has ended up on the wrong floor.
Key points
This is the most useful chapter in the clinic, because it turns a curiosity into an examination reflex: two sites to look at in the same patient, in both directions.
We must begin with some methodological honesty: no prevalence survey in the general population has been published, to our knowledge. Reviews quote incidence figures of the order of one to two cases per hundred thousand people, but these values come from hospital series and not from a representative sample4. An American study based on claims data linked to medical records, whose authors are employees or consultants of a pharmaceutical company (Endo) and employees of a research firm (IQVIA), estimates the prevalence of diagnosed plantar fibromatosis at 57 cases per 100,000 in 2021; the study identifies cases by diagnosis codes, which may confuse them with those of plantar fasciitis (a limitation that we add)23. The profile described by hospital series is that of a middle-aged or older adult, with a male predominance; among the 620 new cases of the American study, however, 63 % were women, which may reflect, in our view, healthcare use23.
Surgical series give consistent benchmarks. In a British series of 18 patients operated on with a partial fasciectomy, the mean age was 41.3 years (range 20 to 57), with 12 men out of 18, and 17 % of patients had multiple nodules at the first consultation5. Cohen's ultrasound series included 43 patients aged 26 to 77 years, with a mean age of 54 years3.
This is the most solid piece of data in the whole chapter, and it comes from the Reykjavík study. One hundred and twenty-two men with Dupuytren's disease were re-invited eighteen years after their initial inclusion, along with as many controls matched for age and smoking. Ninety-two patients and 101 controls attended and were examined for plantar nodules6.
Ledderhose disease was identified in 14 of the 92 men with Dupuytren's disease (15.2 %), versus 4 of the 101 controls (3.9 %), an odds ratio of 4.35 (95 % confidence interval: 1.3 to 16.7; p < 0.01). Two secondary findings deserve as much attention:
The converse was observed in a Dutch prevalence study of 763 randomly selected subjects aged 50 to 89 years: the prevalence of Dupuytren's disease there reached 22.1 %, and the presence of Ledderhose disease was among the significant risk factors for Dupuytren's disease, alongside a history of hand trauma, excessive alcohol consumption and family history7.
Plantar nodules: Dupuytren's disease versus matched controls
Reykjavík cohort, clinical examination of the feet at 18 years of follow-up: 92 affected men, 101 controls matched for age and smoking
Source: Gudmundsson KG, Jónsson T, Arngrímsson R. Association of Morbus Ledderhose with Dupuytren's contracture. Foot Ankle Int 2013;34(6):841-845 (PMID 23386754). Confidence intervals: 1.3-16.7 for the first ratio, 1.8-27.1 for the second.
The notion of Dupuytren's diathesis refers to the clinical features that identify aggressive forms at high risk of recurrence. Its historical version counted ectopic involvement (that is, outside the palm, hence plantar or penile) among its four factors.
A reassessment carried out in 322 patients modified this definition, and the detail matters: the factors were broadened to include male sex and an age at onset below 50 years, but ectopic involvement was restricted to the pads of the interphalangeal joints (Garrod's pads) alone. The presence of all the revised factors raises the risk of recurrence to 71 %, versus 23 % in a patient who has none8.
In other words: Ledderhose disease is not, in the revised version, a formal criterion of diathesis. But the Reykjavík study shows that it preferentially accompanies the most severe palmar forms6. The practical approach is the same under both readings (look at the other site), but the exact wording avoids making a score say what it does not say.
Four benchmarks from the field
Values drawn from the series cited: these are clinical orders of magnitude, not population rates
Sources: Kadir HKA, Chandrasekar CR. Foot 2017;31:31-34 (PMID 28334642); Cohen BE, Murthy NS, McKenzie GA. J Ultrasound Med 2018;37(11):2725-2731 (PMID 29603334).
Key points
Some patients do not have Ledderhose disease: they have a fibromatous disease that expresses itself in several places. This subpopulation deserves to be identified, because it changes the examination, the prognosis and the message.
Superficial fibromatoses form a histologically coherent group. A pathology review devoted to the palmar and plantar forms describes in both the same proliferation of fibroblasts and myofibroblasts, with a common microscopic appearance: bland spindle cells of bluish appearance, with a quantity of background collagen that varies with the age of the lesion1. Clinical reviews add the third site, penile, under the name of Peyronie's disease4.
What distinguishes these three expressions is the mechanical behaviour of the tissue involved, not the nature of the lesion:
| Site | Name | What the lesion does | Main clinical consequence |
|---|---|---|---|
| Palmar aponeurosis | Dupuytren's disease | Nodules, then longitudinal cords that contract1 | Digital contracture, loss of finger extension |
| Plantar aponeurosis | Ledderhose disease | Nodules of the aponeurosis, middle third in 84 % of cases3 ; unusual contracture1 | Mass painful on weight-bearing, discomfort in footwear |
| Penile tunica albuginea | Peyronie's disease | Fibrous plaque of the tunica albuginea4 | Deformity on erection, pain |
The difference between the hand and the foot deserves to be explained to the patient, because it explains why the treatment differs. In the palm, the cord pulls on a mobile finger and surgery has a geometric objective: to restore extension. Under the foot, the nodule is crushed against the ground and surgery has an analgesic objective: to remove the compression. The two diseases share a histology and not a therapeutic logic.
Three actions are enough, and none takes more than a minute:
The strongest signal, however, is not the mere presence of palmar involvement: it is its severity. Men operated on for their Dupuytren's disease, or with an established digital contracture, had six times the risk of having plantar nodules compared with those who had only nodules or cords (odds ratio 6.1; 1.8 to 27.1; p < 0.001)6. In other words, the patient whose shoes should come off first is the one who has already had hand surgery.
What this changes. The examination becomes systematically bilateral and multi-site. Follow-up lengthens, because one site can appear years after the other: the Icelandic cohort re-examined its patients eighteen years after inclusion6. And the message changes: we no longer talk about an isolated nodule but about an underlying predisposition, which helps the patient understand why the disease comes back after surgery.
What this does not change. The treatment of each site remains that of that site. No data indicate that a systemic treatment acts on the whole, and the drugs cited in the reviews (verapamil, tamoxifen, imatinib, sorafenib, mitomycin C) are cited at descriptive levels of evidence, with no established indication49.
Quoting the diathesis without making it say more than it does
The revised version of Dupuytren's diathesis, established in 322 patients, has restricted the ectopic involvement criterion to the pads of the interphalangeal joints (Garrod's pads), and added male sex and onset before 50 years. The presence of all the revised factors raises the risk of recurrence to 71 %, versus 23 % in their absence8. Ledderhose disease therefore does not appear there by name as a criterion, which takes nothing away from its measured association with severe palmar forms6. To say “your plantar involvement is part of your diathesis” is an approximation; to say “it more often accompanies the forms of the hand that recur” is accurate.
Key points

UltrasoundUltrasound and MRI of the foot: nodule of the plantar fascia delineated by arrows, plantar fibromatosis.
Source : Van Hul et al., Insights into imaging, 2011, figure 16 · CC BY
The diagnosis is clinical. It comes down to a well-conducted palpation and three questions, provided you keep in mind what it must above all not be confused with.
Three complaints recur, in this order of frequency: a lump under the foot that the patient discovered while washing or walking barefoot, pain on weight-bearing that increases with prolonged standing and barefoot walking on hard ground, and discomfort in footwear. Kadir's surgical series summarises the reasons for consultation in three items: pain, swelling, and functional discomfort5.
What is not the clinical picture: pain on the first steps on waking, maximal under the heel, easing after a few minutes of walking. That is the picture of plantar fasciopathy, and the distinction is the first one to make.
| Diagnosis | What suggests it | What distinguishes it from plantar fibroma |
|---|---|---|
| Plantar fasciopathy | First-step pain, maximal at the calcaneal insertion, loosening up with walking | No palpable mass; heel pain rather than mid-plantar pain |
| Fibroma of the tendon sheath | Firm mass in contact with a flexor tendon | Not part of the aponeurosis; does not harden with the windlass manoeuvre |
| Synovial cyst or ganglion | Fluctuant, transilluminable mass, often of rapid onset | Anechoic fluid content on ultrasound |
| Morton's neuroma | Forefoot pain between the metatarsal heads, radiating to the toes, Mulder's sign | Anterior location, no fascial mass; see the dedicated article on the site |
| Bursitis or plantar callosity | Point of excessive loading, overlying hyperkeratosis | Superficial skin lesion, moving with the skin |
| Foreign body, granuloma | History of skin breach, local inflammation | Context, inflammatory signs, imaging |
| Soft-tissue sarcoma | Rapid growth, size greater than 5 cm, night pain, deep fixed mass | Absolute red flag: sarcomas have been mistaken for plantar fibromas19 |
Red flags: do not treat, refer

MRIMRI (a, b) and ultrasound (c, d) of the foot: fusiform thickening of the distal plantar fascia, low signal on MRI and hypoechoic on ultrasound, with hypervascularity on Doppler, Ledderhose disease.
Source : Draghi et al., Insights into Imaging, 2017, figure 5 · CC BY
Imaging does not make the diagnosis; it confirms it and, above all, it rules things out. Two publications are enough to know what to request and how to read the report.
The reviews agree: the diagnosis is clinical, and ultrasound and MRI are confirmatory adjuncts, MRI being reserved for aggressive or advanced forms49. Ultrasound has the advantage of being dynamic, comparative and immediate.
The reference series described 57 fibromas in 43 patients and quantified the ultrasound signs3 :
What ultrasound shows in plantar fibromatosis
57 nodules in 43 patients: frequency of each sign
Source: Cohen BE, Murthy NS, McKenzie GA. Ultrasonography of Plantar Fibromatosis: Updated Case Series, Review of the Literature, and a Novel Descriptive Appearance Termed the “Comb Sign”. J Ultrasound Med 2018;37(11):2725-2731 (PMID 29603334).
Two points of interpretation deserve to be stressed, to the patient as to the prescriber. First, intralesional vascularity on Doppler is not a sign of malignancy here : it is present in more than half of the benign fibromas of this series3. Second, the comb sign (this alternation of hypoechoic and isoechoic bands described by these authors) appears all the more readily the larger the nodule, which makes it a useful but not indispensable sign.
MRI is requested when the lesion is large, deep, atypical, or when tumoral doubt persists. It has, however, a shortcoming that must be known before reading an alarming report.
A case published in The Foot concerns a 42-year-old man with a plantar fibromatosis proven histologically, whose MRI showed a so-called “brain gyriform” pattern, an appearance until then described as specific to low-grade fibromyxoid sarcoma. The posterior acoustic enhancement on ultrasound, the T2 hyperintensity and the contrast enhancement were all atypical, and corresponded histologically to areas of high cellularity alternating with fibrous areas poor in cells20.
The practical message is twofold, and it goes both ways: a genuine plantar fibroma can look like a sarcoma on MRI, and a sarcoma can be mistaken for a plantar fibroma19. No imaging replaces pathology when the presentation is out of the ordinary. It is not for the physiotherapist to decide; it is for the physiotherapist to know when not to treat.
Key points
This is a disease in which the physiotherapist is often the first to be consulted and rarely the one who will treat it. Knowing what can be offered, and when to hand over, is worth more than multiplying sessions on a nodule that will not budge.
The most complete systematic review of treatments collated 25 studies and 233 patients. Within this set, only five studies concerned a conservative treatment, totalling 35 patients, against 178 patients operated on15. The authors conclude that clinical trials with standardised outcome measures are still needed to seriously evaluate the success rate and the complications of each procedure.
An older review already stated it: no causal therapy exists, management is symptomatic and graded according to severity, and no long-term randomised controlled study was available for conservative options2. Since then, one exception has appeared, and only one: radiotherapy, which has its own chapter further down.
Objective 1: offload the nodule. This is the measure whose effect is the most immediate and the most reproducible in practice. A plantar orthosis with a cut-out under the nodule, a cushioning insole, footwear with a thick, rigid sole: anything that stops the nodule from being crushed between the ground and the bone reduces weight-bearing pain. No trial has measured this effect in this condition: it is mechanical reasoning, and it must be presented as such.
Objective 2: maintain the flexibility of the posterior chain. A short triceps surae increases the strain on the aponeurosis. Stretches of the gastrocnemius and soleus, and the specific plantar fascia stretch, are commonly offered. Here again, there are no data specific to Ledderhose disease: the transposition comes from plantar fasciopathy, which is a different disease of the same tissue.
Objective 3: monitor. This is a fully fledged physiotherapist's task and it is underestimated. Mapping the nodules, measuring them, noting their number: that is what will make it possible to say in six months whether the disease is progressing, and that is what will trigger referral.
What to avoid. Aggressive techniques directly on the nodule (firm deep transverse massage, prolonged ischaemic pressure, radial shockwaves aimed at “breaking it up” without an established protocol) have no data in their favour and risk a painful worsening of a lesion that, for its part, does not dissolve under the finger. This point rests on reasoning, not on a trial: there is none.
Shockwaves: a special case, not to be confused with massage
Shockwaves of the focused high-energy type have been the subject of a small prospective series: six patients, two sessions seven days apart, 2,000 pulses at 3 Hz and 1.24 mJ/mm². Pain fell from 6 ± 2 before treatment to 2 ± 1 at fourteen days and then 1 ± 1 at three months, with all patients reporting softening of the nodules, without adverse effects12. A case report published in 2024 describes a comparable result in a 48-year-old man with bilateral involvement, with a different protocol: three weekly sessions, 2,000 pulses at 5 Hz and 0.20 mJ/mm²13. Six patients plus one case, without a control group, do not amount to proof: they make a serious lead, with published parameters, and the authors themselves call for larger trials12.
The ranking below applies GRADE principles to the specific question of symptomatic treatment of Ledderhose disease. It is an editorial judgement : to our knowledge, no published GRADE assessment exists for this condition. A consensus recommendation from the German society of radiation oncology (DEGRO 2015) covers radiotherapy for Ledderhose disease among other non-malignant conditions, with levels of evidence from 2c to 4 and grades A to C for all of these conditions24 ; for the rest, the ranking below is entirely our own.
Radiotherapy for symptomatic nodules. The only treatment assessed in a double-blind phase 3 randomised placebo-controlled trial: pain relief in 74 % versus 56 %, a significant difference at 12 and 18 months, with quality of life and barefoot walking speed improved10. Downgraded from “high” for sample size (84 patients) and the absence of independent replication.
Mechanical offloading : plantar orthosis with a cut-out under the nodule, cushioning insole, suitable footwear. Consistent with the pain mechanism and without risk, but no study has measured it in this indication. Recommended by the reviews as part of graded symptomatic treatment2.
Excision surgery, reserved for failure of conservative treatment. Effective on symptoms, but recurrence depends directly on the extent of the resection: 67 % after local resection, 42 % after wide resection, 27 % after fasciectomy16. Retrospective series only.
Focused high-energy shockwaves. A prospective series of six patients12 and a case report13, both without a control group. Parameters published, adverse effects not reported, but the sample size rules out any conclusion on efficacy.
Corticosteroid injection, with or without intralesional fenestration. Two case reports describe a reduction in pain and volume at twelve months after two injections of triamcinolone combined with fenestration14. The authors themselves point out that this option has received only marginal attention in the literature.
Collagenase from Clostridium histolyticum. Described only in isolated case reports, including an ultrasound-guided injection for a recurrence1718. No comparative series, no validated indication in the foot.
Topical verapamil, tamoxifen, imatinib, sorafenib, mitomycin C. Cited by the reviews as options documented at varying levels of evidence, essentially descriptive49. None falls within physiotherapy and none has an established indication.
Stretching and flexibility work of the posterior chain in this indication: no study. Extrapolated from plantar fasciopathy, which is a different disease of the same tissue. Without risk, but to be presented for what it is.
Firm deep transverse massage and ischaemic pressure on the nodule. No data, no plausible mechanism for resorption of mature fibrous tissue, and a risk of painful worsening of a lesion that is already compressed at every step.
Key points
This is the only question in this article that a placebo-controlled randomised trial answers. It deserves to be treated in detail, because it is also the treatment that patients fear most.
The LedRad study is a prospective multicentre randomised double-blind phase 3 trial. Patients were allocated to radiotherapy or to sham radiotherapy: a placebo, therefore, which is exceptional in this field. The primary outcome measure was pain reduction at twelve months on a numerical scale10.
Eighty-four patients were included. The results:
LedRad: radiotherapy versus sham radiotherapy
Double-blind phase 3 randomised trial, 84 patients: mean pain on a numerical scale
Source: de Haan A, van Nes JGH, Kolff MW et al. Radiotherapy for Ledderhose disease: results of the LedRad-study. Radiother Oncol 2023;185:109718 (PMID 37211283).
The same team surveyed by questionnaire all the patients treated with radiotherapy in its centre between 2008 and 2017. One hundred and two feet were irradiated in 67 patients (28 men, 39 women), according to a protocol of two series of five daily fractions of 3 Gy11.
Mean pain fell from 5.7 before treatment to 1.7 at the time of evaluation (p < 0.001). The detail of the response is more instructive than the mean: complete response (disappearance of pain) for 42 feet (41 %), partial response for 38 feet (37 %), no change for 22 feet (22 %), and worsening for none. Seventy-eight per cent of patients said they were satisfied, 57 % did not find the treatment burdensome, and quality-of-life scores were comparable to those of the Dutch population of the same age. The most frequent residual adverse effect was dry skin, in 10 patients (15 %)11.
One patient in five gets nothing from radiotherapy, none comes out worse, and two in five no longer have any pain at all: it is the only treatment of this disease for which this can be stated with a figure.
What the physiotherapist can say about it to the patient
The word “radiotherapy” evokes cancer, and many patients refuse before listening. Three factual elements are enough to restore a sense of proportion: it involves low doses (two series of five 3 Gy sessions in the published protocol11), the reported adverse effects are cutaneous and mild in 95 % of cases and resolved in 87 % of patients at eighteen months10, and it is the only treatment of this disease to have been compared with a placebo in a double-blind design. The decision rests with the doctor; the factual information, for its part, is given in the session.
Key points
Surgery relieves, and it recurs. These two facts do not contradict each other: they are explained by a single variable, the extent of what is removed.
This is the most useful result in the whole surgical literature on this disease. A systematic review combined with a personal series compiled six studies covering 109 feet in 92 patients, and classified recurrence according to the procedure performed16 :
Recurrence after surgery, by extent of resection
Systematic review of six studies, 109 feet in 92 patients
Source: Anwander H, Weichsel F, Cullmann J et al. Recurrence Rate After Wide Resection of Plantar Fibromatosis: A Case Series and Systematic Literature Review. Foot Ankle Spec 2024;17(2):109-116 (PMID 34369197).
The authors draw an explicit recommendation from this: prefer wide resection or fasciectomy to local resection, because of the markedly lower recurrence rate16. Their own series of 12 patients reviewed between 2 and 13 years after a wide resection shows 2 recurrences (17 %) at a mean follow-up of 7.8 years, with a median foot functional index (Foot Functional Index) of 1 and a median AOFAS score of 95; in other words, excellent functional results in those who do not relapse.
A British series offers a useful counterpoint. Eighteen patients, nineteen partial fasciectomies, with up to five years of follow-up: only one recurrence (6 %), but 17 % scar problems (two cases of scar pain and one hypersensitive scar resolved at twelve months)5. This last point is not trivial in a region that bears body weight: a painful plantar scar can be more disabling than the nodule it has replaced.
The rule accepted by all the reviews is simple: surgery comes after failure of conservative treatment, never before915. The criteria that tip the balance:
And a common-sense contraindication that the literature suggests through its figures: an asymptomatic nodule is not operated on. A two-in-three recurrence rate after local resection is not a reasonable price to pay to remove a lump that does not hurt.
Key points
Four published situations, taken as they are with their identifiers. Two show what treatment can do, two show what imaging cannot.
Case 1: Bilateral involvement treated with shockwaves
Fulceri F, Ryskalin L, Morucci G et al. Life 2024;14(2):16913 (free full text, PMC10889909).
A 48-year-old man presents with bilateral Ledderhose disease. The protocol applied comprised three sessions one week apart, 2,000 pulses at 5 Hz, energy flux density of 0.20 mJ/mm², with ultrasound follow-up. The reported result is complete disappearance of pain, restoration of full functional activity and a marked improvement in quality of life.
What this case teaches, and what it does not. It documents precise, reproducible parameters, which this field sorely lacks; the authors themselves note that the literature on shockwaves in this indication is “extremely limited” and that no optimal parameter has been defined. But a single case without a control group, in a disease that fluctuates, does not demonstrate efficacy.
Case 2: Two nodules treated with fenestration and corticosteroids
Flanagan G, Burt N, Reilly IN. SAGE Open Med Case Rep 2021;9:2050313X21101181314 (free full text, PMC8107658).
Two patients with painful plantar nodules each received, on two occasions, an intralesional fenestration combined with an injection of triamcinolone acetonide mixed with a local anaesthetic. At twelve months, the authors report a significant reduction in pain and in lesion volume.
What this case teaches. The authors open their article by noting that corticosteroid injection has received, in this disease, no more than a passing mention in the scientific literature. This is exactly the problem of the field: widespread practices, almost never evaluated. Two patients do not change this observation, but they describe a protocol that others will be able to reproduce.
Case 3: A sarcoma mistaken for a plantar fibroma
Lockyer MG, Rosen DG. Anticancer Res 2015;35(11):6171-617419.
A 44-year-old man presents with a mass of the medial arch of the foot, initially considered to be a plantar fibroma. MRI showed a lobulated subcutaneous mass, inseparable from the fascia. Microscopic examination revealed an extraskeletal myxoid chondrosarcoma (a rare tumour, indolent in course but with a high potential for local recurrence and metastasis).
What this case teaches. The authors conclude that this diagnosis must always be considered in the presence of a mass of the plantar fascia. For the physiotherapist, the translation is direct: a plantar mass that grows, that exceeds a few centimetres or that comes with night pain is not treated; it is referred.
Case 4: A plantar fibroma that, for its part, looked like a sarcoma
Touraine S, Bousson V, Kaci R et al. The Foot 2013;23(2-3):88-9220.
A 42-year-old man with a plantar fibromatosis histologically proven showed on MRI a “brain gyriform” pattern previously described as exclusive to low-grade fibromyxoid sarcoma, with posterior acoustic enhancement on ultrasound, T2 hyperintensity and contrast enhancement, all of them atypical. Histology showed that this pattern corresponded to the juxtaposition of highly cellular areas and fibrous areas poor in cells.
What this case teaches. This is the exact mirror of the previous one, and the two go together. Imaging is wrong in both directions; only pathology settles it. An alarming MRI report no more condemns the patient than a reassuring report puts them out of harm's way.
Key points
A rare disease, for which the only learned-society recommendation found concerns a treatment that does not fall to us, radiotherapy: the physiotherapist's role in it is real, but it must be defined precisely so as not to stray into useless sessions.
| What is measured | Why | Frequency |
|---|---|---|
| Number and size of nodules | The only objective marker of progression; multiple nodules affect 17 % of patients from the first consultation5 | Every 2 to 3 months |
| Pain on weight-bearing on a numerical scale | This is the primary outcome measure of the LedRad trial, which makes the values comparable with the literature10 | At each assessment |
| Walking distance and tolerance of standing | Direct functional translation; barefoot walking speed was a secondary outcome of LedRad10 | At each assessment |
| Examination of the palms | Screening for an associated Dupuytren's disease, the prevalence of which is multiplied by four in this context6 | Initial, then annual |
| Toe mobility | Contracture is rare but it marks an advanced form1 | At each assessment |
| Tolerance of the orthosis | Poorly placed offloading moves the strain instead of removing it | At 3 weeks, then at each assessment |
It is unlikely. Ledderhose disease is a fibrous proliferation; no regular spontaneous regression is described, and no causal treatment exists2. On the other hand, a nodule can remain stable and painless for years, in which case there is nothing to do, and that is good news that should be announced as such.
The link exists and it has been quantified: in the Reykjavík cohort, 15.2 % of men with Dupuytren's disease had plantar nodules versus 3.9 % of controls6, and the presence of Ledderhose disease is among the risk factors for Dupuytren's disease in a Dutch population study7. This justifies examining the palms, not becoming alarmed: most patients will not have both.
No: it is a benign lesion1. But the question is legitimate, because rare malignant tumours can present in exactly the same way19. This is precisely why a mass that grows quickly, that exceeds a few centimetres or that wakes you at night is investigated before it is treated.
Only after failure of conservative treatment915, and never on a painless nodule. The point to know before deciding: recurrence depends on the extent of the resection: 67 % after removal of the nodule alone, 42 % after wide resection, 27 % after fasciectomy16. A partial fasciectomy also led to 17 % scar problems in a series of 18 patients5, which is no small matter under a foot.
No study has measured it in this disease. The mechanical reasoning is sound (a nodule of the middle third of the arch is compressed at every step between the ground and the bone, and the cut-out removes this compression) and the risk is nil. It is a common-sense intervention, to be offered as such and not as a validated treatment.
Nothing forbids it and nothing encourages it: the question has not been studied. The practical guide is weight-bearing pain, which governs. Change the surface, the shoe and the volume before stopping, and adapt the orthosis to the sports shoe, which does not have the same internal volume as an everyday shoe.
In the phase 3 randomised trial, the adverse effects (erythema, dry skin, burning sensations, transient worsening of pain) were of mild grade in 95 % of cases and resolved in 87 % of patients at eighteen months10. In the long-term follow-up cohort, the most frequent residual effect was dry skin in 15 % of patients11. The decision rests with the doctor; the factual information is given in the session.
The available literature is a prospective series of six patients and one case report, both without a control group1213. The reported results are favourable and the parameters are published (shockwaves that are focused and of high energy, not radial), but the sample size rules out any conclusion. To be offered, where appropriate, as a therapeutic trial whose level of evidence is stated.
On the same subject
Each reference was individually verified in PubMed: identifier resolved, journal, year, volume and author list checked, abstract read to make sure that the source does establish what is attributed to it.
Method and limitations
Sources searched in PubMed via the NCBI E-utilities services, crossing plantar fibromatosis and Ledderhose disease with epidemiology, imaging, radiotherapy, shockwaves, injections, collagenase and surgery. Each identifier was resolved and each abstract read before citation. Main limitation: only one randomised trial exists in this disease, and it concerns radiotherapy; everything else rests on retrospective series and case reports. The levels of evidence in the table of modalities are an editorial judgement applying GRADE principles, and not a published GRADE assessment; the only learned-society recommendation found is a German radiation oncology consensus (DEGRO 2015), which covers the disease among other non-malignant conditions. One reference was moreover set aside during the work: an article whose title announced a case of bilateral plantar fibromatosis but whose indexed abstract described an entirely different patient: inconsistent metadata, hence not cited. Article written on 14 August 2026.